Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients - Full Text View

Purpose

To date, one clinical trial, RAPIDS-1, was performed in Scleroderma patients with or without digital ulcers at baseline. The RAPIDS-1 study results showed that Bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of this trial is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24 week treatment period.

Condition	Intervention	Phase
Systemic Sclerosis Scleroderma	Drug: Bosentan	Phase III

MedlinePlus related topics:

Scleroderma

Drug Information available for:

Bosentan

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis

Further study details as provided by Actelion:

Primary Outcome Measures:

Time to complete healing of the cardinal ulcer up to week 24 whose healing is maintained for 12 weeks
Total number of new digital ulcers per patient up to week 24

Secondary Outcome Measures:

Hand functionality and pain
Tolerability and safety

Estimated Enrollment:	180
Study Start Date:	September 2003
Estimated Study Completion Date:	December 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main Inclusion Criteria:

Systemic Sclerosis (SSc), diffuse or limited
SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer.

Main Exclusion Criteria:

Digital ulcers due to conditions other than SSc.
Severe pulmonary arterial hypertension (PAH) (Who class III and IV).
Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any life- threatening condition.
Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization.
Treatment with inhaled or oral prostanoids one month prior to randomization.
Previous treatment with bosentan.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077584

Show 25 Study Locations

Sponsors and Collaborators

Actelion

Investigators


Principal Investigator:	Carol M. Black, MD	Royal Free Hospital, Centre for Rheumatology, London, UK

Principal Investigator:	Daniel Furst, MD	UCLA School of Medicine, Los Angeles, CA, USA

Principal Investigator:	Joseph H. Korn, MD	Boston University School of Medicine, Boston, MA, USA

Principal Investigator:	Marco Matucci, MD	Universita Degli Studi, E Terapia Medica IV, Florence, Italy

Principal Investigator:	Maureen Mayes, MD	University of Texas, Medical Branch, 6431 Fannin Street, Houston, TX, USA

Principal Investigator:	James Seibold, MD	Robert Wood Johnson Medical School, New Brunswick, NJ, USA

More Information

Study ID Numbers:	RAPIDS-2 / AC-052-331
First Received:	February 10, 2004
Last Updated:	February 27, 2006
ClinicalTrials.gov Identifier:	NCT00077584
Health Authority:	United States: Food and Drug Administration

Keywords provided by Actelion:

Digital Ulcers

Finger Ulcers

Systemic Sclerosis

Scleroderma

Study placed in the following topic categories:

Skin Diseases

Ulcer

Connective Tissue Diseases

Sclerosis

Scleroderma, Systemic

Ischemia

Bosentan

Additional relevant MeSH terms:

Pathologic Processes

Therapeutic Uses

Cardiovascular Agents

Antihypertensive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	Actelion
Information provided by:	Actelion
ClinicalTrials.gov Identifier:	NCT00077584